Tailored treatment strategies and future directions in systemic lupus erythematosus.
Phenotypes
Recommendations
Systemic lupus erythematosus
Treatment
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
07
03
2022
accepted:
02
04
2022
pubmed:
23
4
2022
medline:
20
7
2022
entrez:
22
4
2022
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE) represents a diagnostic and therapeutic challenge for physicians due to its protean manifestations and unpredictable course. The disease may manifest as multisystemic or organ-dominant and severity at presentation may vary according to age at onset (childhood-, adult- or late-onset SLE). Different manifestations may respond variably to different immunosuppressive medications and, even within the same organ-system, the severity of inflammation may vary from mild to organ-threatening. Current "state-of-the-art" in SLE treatment aims at remission or low disease activity in all organ systems. Apart from hydroxychloroquine and glucocorticoids (which should be used with caution), the choice of the appropriate immunosuppressive agent should be individualized and depend on the prevailing manifestation, severity stratification and patient childbearing potential. In this review, we provide an overview of therapeutic options for the various organ manifestations and severity patterns of the disease, different phenotypes (such as multisystem versus organ-dominant disease), as well as specific considerations, including lupus with antiphospholipid antibodies, childhood and late-onset disease, as well as treatment options during pregnancy and lactation.
Identifiants
pubmed: 35449237
doi: 10.1007/s00296-022-05133-0
pii: 10.1007/s00296-022-05133-0
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Glucocorticoids
0
Immunosuppressive Agents
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1307-1319Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Kaul A, Gordon C, Crow MK et al (2016) Systemic lupus erythematosus. Nat Rev Dis Primers 2:16039. https://doi.org/10.1038/nrdp.2016.39
doi: 10.1038/nrdp.2016.39
pubmed: 27306639
Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11:593–595. https://doi.org/10.1016/j.autrev.2011.10.020
doi: 10.1016/j.autrev.2011.10.020
pubmed: 22041578
Lever E, Alves MR, Isenberg DA (2020) Towards precision medicine in systemic lupus erythematosus. PGPM 13:39–49. https://doi.org/10.2147/PGPM.S205079
doi: 10.2147/PGPM.S205079
pubmed: 32099443
pmcid: 7007776
Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT (2021) Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80:14–25. https://doi.org/10.1136/annrheumdis-2020-218272
doi: 10.1136/annrheumdis-2020-218272
pubmed: 33051219
Furie RA, Petri MA, Wallace DJ et al (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61:1143–1151. https://doi.org/10.1002/art.24698
doi: 10.1002/art.24698
pubmed: 19714615
pmcid: 2748175
Wallace DJ, Kalunian K, Petri MA et al (2014) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73:183–190. https://doi.org/10.1136/annrheumdis-2012-202760
doi: 10.1136/annrheumdis-2012-202760
pubmed: 23313811
Furie RA, Morand EF, Bruce IN et al (2019) Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 1:e208–e219. https://doi.org/10.1016/S2665-9913(19)30076-1
doi: 10.1016/S2665-9913(19)30076-1
Morand EF, Furie R, Tanaka Y et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382:211–221. https://doi.org/10.1056/NEJMoa1912196
doi: 10.1056/NEJMoa1912196
pubmed: 31851795
Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736–745. https://doi.org/10.1136/annrheumdis-2019-215089
doi: 10.1136/annrheumdis-2019-215089
pubmed: 30926722
Mok CC, Ho LY, Tse SM, Chan KL (2017) Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 76:1420–1425. https://doi.org/10.1136/annrheumdis-2016-210382
doi: 10.1136/annrheumdis-2016-210382
pubmed: 28432050
Piga M, Floris A, Cappellazzo G et al (2017) Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther 19:247. https://doi.org/10.1186/s13075-017-1451-5
doi: 10.1186/s13075-017-1451-5
pubmed: 29126432
pmcid: 5681839
Zen M, Iaccarino L, Gatto M et al (2018) Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 77:104–110. https://doi.org/10.1136/annrheumdis-2017-211613
doi: 10.1136/annrheumdis-2017-211613
pubmed: 28970217
Kapsala N, Nikolopoulos D, Flouda S et al (2021) First diagnosis of systemic lupus erythematosus in hospitalized patients: clinical phenotypes and pitfalls for the non-specialist. Am J Med. https://doi.org/10.1016/j.amjmed.2021.07.015
doi: 10.1016/j.amjmed.2021.07.015
pubmed: 34411524
Adamichou C, Nikolopoulos D, Genitsaridi I et al (2020) In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis 79:232–241. https://doi.org/10.1136/annrheumdis-2019-216155
doi: 10.1136/annrheumdis-2019-216155
pubmed: 31704720
Kuhn A, Aberer E, Bata-Csörgő Z et al (2017) S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 31:389–404. https://doi.org/10.1111/jdv.14053
doi: 10.1111/jdv.14053
pubmed: 27859683
Parisis D, Bernier C, Chasset F, Arnaud L (2019) Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 18:102393. https://doi.org/10.1016/j.autrev.2019.102393
doi: 10.1016/j.autrev.2019.102393
pubmed: 31520802
Shipman WD, Vernice NA, Demetres M, Jorizzo JL (2020) An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review. J Am Acad Dermatol 82:709–722. https://doi.org/10.1016/j.jaad.2019.07.027
doi: 10.1016/j.jaad.2019.07.027
pubmed: 31306730
Chasset F, Bouaziz J-D, Costedoat-Chalumeau N et al (2017) Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol 177:188–196. https://doi.org/10.1111/bjd.15312
doi: 10.1111/bjd.15312
pubmed: 28112801
Ugarte A, Porta S, Ríos R et al (2018) Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Lupus 27:1718–1722. https://doi.org/10.1177/0961203318768877
doi: 10.1177/0961203318768877
pubmed: 29635998
Chasset F, Arnaud L, Jachiet M et al (2018) Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study. J Am Acad Dermatol 78:107-114.e1. https://doi.org/10.1016/j.jaad.2017.08.045
doi: 10.1016/j.jaad.2017.08.045
pubmed: 29061479
Yuki EFN, Silva CA, Aikawa NE et al (2019) Thalidomide and lenalidomide for refractory systemic/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice. JCR: J Clin Rheumatol. https://doi.org/10.1097/RHU.0000000000001160
doi: 10.1097/RHU.0000000000001160
Merrill JT, Werth V, Furie R et al (2021) OP0131 anifrolumab effects on rash and arthritis in patients with SLE and impact of interferon signal in pooled data from phase 3 trials. Ann Rheum Dis 80:75–76
doi: 10.1136/annrheumdis-2021-eular.1471
Fanouriakis A, Adamichou C, Koutsoviti S et al (2018) Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: a real-life observational study. Semin Arthritis Rheum. https://doi.org/10.1016/j.semarthrit.2018.02.014
doi: 10.1016/j.semarthrit.2018.02.014
pubmed: 29555348
Iaccarino L, Bettio S, Reggia R et al (2017) Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken) 69:115–123. https://doi.org/10.1002/acr.22971
doi: 10.1002/acr.22971
Tani C, D’Aniello D, Sedie AD et al (2013) Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev 12:537–541. https://doi.org/10.1016/j.autrev.2012.09.004
doi: 10.1016/j.autrev.2012.09.004
pubmed: 23063507
Wang H, Ren Y, Chang J et al (2018) A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol 33:17–25. https://doi.org/10.5606/ArchRheumatol.2017.6127
doi: 10.5606/ArchRheumatol.2017.6127
pubmed: 29900975
Hanly JG, O’Keeffe AG, Su L et al (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55:252–262. https://doi.org/10.1093/rheumatology/kev311
doi: 10.1093/rheumatology/kev311
Fanouriakis A, Kostopoulou M, Cheema K et al (2020) 2019 update of the joint european league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-216924
doi: 10.1136/annrheumdis-2020-216924
pubmed: 33051219
Rovin BH, Adler SG, Barratt J et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1–S276. https://doi.org/10.1016/j.kint.2021.05.021
doi: 10.1016/j.kint.2021.05.021
Liu Z, Zhang H, Xing C et al (2015) Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162:18–26. https://doi.org/10.7326/M14-1030
doi: 10.7326/M14-1030
pubmed: 25383558
Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117–1128. https://doi.org/10.1056/NEJMoa2001180
doi: 10.1056/NEJMoa2001180
pubmed: 32937045
Rovin BH, Teng YKO, Ginzler EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070–2080. https://doi.org/10.1016/S0140-6736(21)00578-X
doi: 10.1016/S0140-6736(21)00578-X
pubmed: 33971155
Furie RA, Aroca G, Cascino MD et al (2021) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220920
doi: 10.1136/annrheumdis-2021-220920
pubmed: 34615636
Anders H-J, Lei Y, Rovin BH (2021) Induction and maintenance therapy of lupus nephritis: an obituary. Kidney Int 99:288–291. https://doi.org/10.1016/j.kint.2020.11.009
doi: 10.1016/j.kint.2020.11.009
pubmed: 33509346
Parodis I, Houssiau FA (2021) From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift? Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-221270
doi: 10.1136/annrheumdis-2021-221270
pubmed: 34521616
Hermosillo-Romo D, Brey RL (2002) Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol 16:229–244. https://doi.org/10.1053/berh.2001.0223
doi: 10.1053/berh.2001.0223
pubmed: 12041951
Nikolopoulos D, Fanouriakis A, Bertsias G (2021) Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. Expert Rev Clin Immunol 17:317–330. https://doi.org/10.1080/1744666X.2021.1899810
doi: 10.1080/1744666X.2021.1899810
pubmed: 33682602
Pamfil C, Fanouriakis A, Damian L et al (2015) EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology 54:1270–1278. https://doi.org/10.1093/rheumatology/keu482
doi: 10.1093/rheumatology/keu482
pubmed: 25638807
Nikolopoulos D, Fanouriakis A, Boumpas D (2019) Cerebrovascular events in systemic lupus erythematosus: diagnosis and management. Mediterr J Rheumatol 30:7–15. https://doi.org/10.31138/mjr.30.1.7
doi: 10.31138/mjr.30.1.7
pubmed: 32185337
pmcid: 7045913
Bertsias GK, Ioannidis JP, Aringer M et al (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69:2074–82. https://doi.org/10.1136/ard.2010.130476
doi: 10.1136/ard.2010.130476
pubmed: 20724309
Fanouriakis A, Pamfil C, Sidiropoulos P et al (2016) Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus 25:627–636. https://doi.org/10.1177/0961203315622821
doi: 10.1177/0961203315622821
pubmed: 26692040
Bortoluzzi A, Padovan M, Farina I et al (2012) Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre. Reumatismo 64:350–359. https://doi.org/10.4081/reumatismo.2012.350
doi: 10.4081/reumatismo.2012.350
pubmed: 23285478
Gupta N, Ganpati A, Mandal S et al (2017) Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India. Clin Rheumatol 36:2273–2279. https://doi.org/10.1007/s10067-017-3775-6
doi: 10.1007/s10067-017-3775-6
pubmed: 28785855
Velo-García A, Castro SG, Isenberg DA (2016) The diagnosis and management of the haematologic manifestations of lupus. J Autoimmun 74:139–160. https://doi.org/10.1016/j.jaut.2016.07.001
doi: 10.1016/j.jaut.2016.07.001
pubmed: 27461045
Pistiner M, Wallace DJ, Nessim S et al (1991) Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21:55–64. https://doi.org/10.1016/0049-0172(91)90057-7
doi: 10.1016/0049-0172(91)90057-7
pubmed: 1948102
Zhu F, Huang J-Y, Wen Q et al (2020) Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217013
doi: 10.1136/annrheumdis-2020-217013
pubmed: 32988836
Fanouriakis A, Bertsias G, Boumpas DT (2020) Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or ‘blood-dominant’ lupus? Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217356
doi: 10.1136/annrheumdis-2020-217356
pubmed: 33051219
Bradbury CA, Pell J, Hill Q et al (2021) Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med 385:885–895. https://doi.org/10.1056/NEJMoa2100596
doi: 10.1056/NEJMoa2100596
pubmed: 34469646
Khellaf M, Charles-Nelson A, Fain O et al (2014) Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 124:3228–3236. https://doi.org/10.1182/blood-2014-06-582346
doi: 10.1182/blood-2014-06-582346
pubmed: 25293768
Steiman AJ, Gladman DD, Ibanez D, Urowitz MB (2010) Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 37:1822–7. https://doi.org/10.3899/jrheum.100007
doi: 10.3899/jrheum.100007
pubmed: 20595281
Huang H, Mu L, Zhang Z et al (2021) Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study. Arthritis Res Ther 23:275. https://doi.org/10.1186/s13075-021-02641-5
doi: 10.1186/s13075-021-02641-5
pubmed: 34715915
pmcid: 8556984
Steiman AJ, Gladman DD, Ibanez D, Urowitz MB (2012) Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken) 64:511–518. https://doi.org/10.1002/acr.21568
doi: 10.1002/acr.21568
Conti F, Ceccarelli F, Perricone C et al (2016) The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. Lupus 25:719–726. https://doi.org/10.1177/0961203315627199
doi: 10.1177/0961203315627199
pubmed: 26821965
Govoni M, Bombardieri S, Bortoluzzi A et al (2012) Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology 51:157–168. https://doi.org/10.1093/rheumatology/ker310
doi: 10.1093/rheumatology/ker310
pubmed: 22075066
Fayyaz A, Igoe A, Kurien BT et al (2015) Haematological manifestations of lupus. Lupus Sci Med 2:e000078–e000078. https://doi.org/10.1136/lupus-2014-000078
doi: 10.1136/lupus-2014-000078
pubmed: 25861458
pmcid: 4378375
Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78:1296–1304. https://doi.org/10.1136/annrheumdis-2019-215213
doi: 10.1136/annrheumdis-2019-215213
pubmed: 31092409
Arnaud L, Mathian A, Ruffatti A et al (2014) Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 13:281–291. https://doi.org/10.1016/j.autrev.2013.10.014
doi: 10.1016/j.autrev.2013.10.014
pubmed: 24189281
Andreoli L, Bertsias GK, Agmon-Levin N et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76:476–485. https://doi.org/10.1136/annrheumdis-2016-209770
doi: 10.1136/annrheumdis-2016-209770
pubmed: 27457513
Clowse MEB (2007) Lupus activity in pregnancy. Rheum Dis Clin N Am 33:237–252. https://doi.org/10.1016/j.rdc.2007.01.002
doi: 10.1016/j.rdc.2007.01.002
Götestam Skorpen C, Lydersen S, Gilboe I et al (2017) Disease activity during pregnancy and the first year postpartum in women with systemic lupus erythematosus. Arthritis Care Res 69:1201–1208. https://doi.org/10.1002/acr.23102
doi: 10.1002/acr.23102
Buyon JP, Kim MY, Guerra MM et al (2015) Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 163:153–163. https://doi.org/10.7326/M14-2235
doi: 10.7326/M14-2235
pubmed: 26098843
pmcid: 5113288
Lateef A, Petri M (2012) Management of pregnancy in systemic lupus erythematosus. Nat Rev Rheumatol 8:710–718. https://doi.org/10.1038/nrrheum.2012.133
doi: 10.1038/nrrheum.2012.133
pubmed: 22907290
Lightstone L, Hladunewich MA (2017) Lupus nephritis and pregnancy: concerns and management. Semin Nephrol 37:347–353. https://doi.org/10.1016/j.semnephrol.2017.05.006
doi: 10.1016/j.semnephrol.2017.05.006
pubmed: 28711073
Knight C, Nelson-Piercy C (2017) Management of systemic lupus erythematosus during pregnancy: challenges and solutions. OARRR 9:37–53. https://doi.org/10.2147/OARRR.S87828
doi: 10.2147/OARRR.S87828
Izmirly PM, Costedoat-Chalumeau N, Pisoni CN et al (2012) Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 126:76–82. https://doi.org/10.1161/CIRCULATIONAHA.111.089268
doi: 10.1161/CIRCULATIONAHA.111.089268
pubmed: 22626746
pmcid: 3437628
Eudy AM, Siega-Riz AM, Engel SM et al (2018) Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2017-212535
doi: 10.1136/annrheumdis-2017-212535
pubmed: 29643109
Götestam Skorpen C, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795–810. https://doi.org/10.1136/annrheumdis-2015-208840
doi: 10.1136/annrheumdis-2015-208840
pubmed: 26888948
ACOG (2018) ACOG committee opinion no. 743: low-dose aspirin use during pregnancy. Obstet Gynecol 132:e44–e52. https://doi.org/10.1097/AOG.0000000000002708`
doi: 10.1097/AOG.0000000000002708`
Sammaritano LR, Bermas BL, Chakravarty EE et al (2020) 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72:529–556. https://doi.org/10.1002/art.41191
doi: 10.1002/art.41191
pubmed: 32090480
Imbasciati E, Tincani A, Gregorini G et al (2008) Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 24:519–525. https://doi.org/10.1093/ndt/gfn348
doi: 10.1093/ndt/gfn348
pubmed: 18565977
Moroni G, Doria A, Giglio E et al (2016) Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J Autoimmun 74:194–200. https://doi.org/10.1016/j.jaut.2016.06.012
doi: 10.1016/j.jaut.2016.06.012
pubmed: 27373903
Hedrich CM, Smith EMD, Beresford MW (2017) Juvenile-onset systemic lupus erythematosus (jSLE) – pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol 31:488–504. https://doi.org/10.1016/j.berh.2018.02.001
doi: 10.1016/j.berh.2018.02.001
pubmed: 29773269
Tucker L, Uribe A, Fernández M et al (2008) Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case–control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 17:314–322. https://doi.org/10.1177/0961203307087875
doi: 10.1177/0961203307087875
pubmed: 18413413
pmcid: 2818044
Descloux E, Durieu I, Cochat P et al (2009) Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology 48:779–784. https://doi.org/10.1093/rheumatology/kep067
doi: 10.1093/rheumatology/kep067
pubmed: 19416945
Massias JS, Smith EMD, Al-Abadi E et al (2020) Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus 29:474–481. https://doi.org/10.1177/0961203320909156
doi: 10.1177/0961203320909156
pubmed: 32233733
pmcid: 7528537
Groot N, de Graeff N, Avcin T et al (2017) European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 76:1788–1796. https://doi.org/10.1136/annrheumdis-2016-210960
doi: 10.1136/annrheumdis-2016-210960
pubmed: 28630236
Groot N, de Graeff N, Marks SD et al (2017) European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 76:1965–1973. https://doi.org/10.1136/annrheumdis-2017-211898
doi: 10.1136/annrheumdis-2017-211898
pubmed: 28877866
Brunner HI, Abud-Mendoza C, Viola DO et al (2020) Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 79:1340–1348. https://doi.org/10.1136/annrheumdis-2020-217101
doi: 10.1136/annrheumdis-2020-217101
pubmed: 32699034
Mina R, von Scheven E, Ardoin SP et al (2012) Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res 64:375–383. https://doi.org/10.1002/acr.21558
doi: 10.1002/acr.21558
Chalhoub NE, Wenderfer SE, Levy DM et al (2021) International consensus for the dosing of corticosteroids in childhood-onset systemic lupus erythematosus with proliferative lupus nephritis. Arthritis Rheumatol. https://doi.org/10.1002/art.41930
doi: 10.1002/art.41930
Mao Y, Yin L, Huang H et al (2019) Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. J Int Med Res 47:105–113. https://doi.org/10.1177/0300060518796751
doi: 10.1177/0300060518796751
pubmed: 30208769
Tanaka H (2012) Treatment of young patients with lupus nephritis using calcineurin inhibitors. WJN 1:177. https://doi.org/10.5527/wjn.v1.i6.177
doi: 10.5527/wjn.v1.i6.177
pubmed: 24175257
pmcid: 3782217
Groot N, de Graeff N, Avcin T et al (2017) European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis 76:1637–1641. https://doi.org/10.1136/annrheumdis-2016-211001
doi: 10.1136/annrheumdis-2016-211001
pubmed: 28473426
Mekinian A, Lachassinne E, Nicaise-Roland P et al (2013) European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis 72:217–222. https://doi.org/10.1136/annrheumdis-2011-201167
doi: 10.1136/annrheumdis-2011-201167
pubmed: 22589374
Lalani S, Pope J, de Leon F, Peschken C (2010) Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol 37:38–44. https://doi.org/10.3899/jrheum.080957
doi: 10.3899/jrheum.080957
pubmed: 20008925
Sohn IW, Joo YB, Won S, Bae SC (2018) Late-onset systemic lupus erythematosus: is it “mild lupus”? Lupus 27:235–242. https://doi.org/10.1177/0961203317716789
doi: 10.1177/0961203317716789
pubmed: 28650278
Feng X, Zou Y, Pan W et al (2014) Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus. Lupus 23:327–334. https://doi.org/10.1177/0961203313513508
doi: 10.1177/0961203313513508
pubmed: 24297642
Chassin MR, Loeb JM, Schmaltz SP, Wachter RM (2010) Accountability measures — using measurement to promote quality improvement. N Engl J Med 363:683–688. https://doi.org/10.1056/NEJMsb1002320
doi: 10.1056/NEJMsb1002320
pubmed: 20573915
McGlynn EA, Asch SM, Adams J et al (2003) The quality of health care delivered to adults in the United States. N Engl J Med 348:2635–2645. https://doi.org/10.1056/NEJMsa022615
doi: 10.1056/NEJMsa022615
pubmed: 12826639
Chavatza K, Kostopoulou M, Nikolopoulos D et al (2021) Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. Ann Rheum Dis 80:1175–1182. https://doi.org/10.1136/annrheumdis-2021-220438
doi: 10.1136/annrheumdis-2021-220438
pubmed: 34162597
Klavdianou K, Lazarini A, Fanouriakis A (2020) Targeted biologic therapy for systemic lupus erythematosus: emerging pathways and drug pipeline. BioDrugs 34:133–147. https://doi.org/10.1007/s40259-020-00405-2
doi: 10.1007/s40259-020-00405-2
pubmed: 32002918
Rovin BH, van Vollenhoven RF, Aranow C et al (2016) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis: ANTI-IL-6 mAb sirukumab in active lupus nephritiS. Arthritis Rheumatol 68:2174–2183. https://doi.org/10.1002/art.39722
doi: 10.1002/art.39722
pubmed: 27110697
pmcid: 5129491
Furie R, Nicholls K, Cheng TT et al (2014) Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66:379–389. https://doi.org/10.1002/art.38260
doi: 10.1002/art.38260
pubmed: 24504810
Isenberg D, Furie R, Jones NS et al (2020) OP0233 efficacy, safety, and pharmacodynamic effects of the bruton’s tyrosine kinase inhibitor, fenebrutinib (GDC-0853), in moderate to severe systemic lupus erythematosus in a phase 2 controlled study. Ann Rheum Dis 79(148):1–148. https://doi.org/10.1136/annrheumdis-2020-eular.2949
doi: 10.1136/annrheumdis-2020-eular.2949
Furie RA, Bruce IN, Dörner T et al (2021) Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology 60:5397–5407. https://doi.org/10.1093/rheumatology/keab381
doi: 10.1093/rheumatology/keab381
pubmed: 33956056
pmcid: 9194804
Clowse ME, Wallace DJ, Furie RA et al (2017) Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol 69:362–375. https://doi.org/10.1002/art.39856
doi: 10.1002/art.39856
pubmed: 27598855
pmcid: 5299488
Merrill JT, Werth VP, Furie R et al (2022) Phase 2 trial of iberdomide in systemic lupus erythematosus. N Engl J Med 386:1034–1045. https://doi.org/10.1056/NEJMoa2106535
doi: 10.1056/NEJMoa2106535
pubmed: 35294813
He J, Zhang R, Shao M et al (2020) Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 79:141–149. https://doi.org/10.1136/annrheumdis-2019-215396
doi: 10.1136/annrheumdis-2019-215396
pubmed: 31537547
Mougiakakos D, Krönke G, Völkl S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385:567–569. https://doi.org/10.1056/NEJMc2107725
doi: 10.1056/NEJMc2107725
pubmed: 34347960
Houssiau FA, Thanou A, Mazur M et al (2020) IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis 79:347–355. https://doi.org/10.1136/annrheumdis-2019-216379
doi: 10.1136/annrheumdis-2019-216379
pubmed: 31871140
Kegerreis B, Catalina MD, Bachali P et al (2019) Machine learning approaches to predict lupus disease activity from gene expression data. Sci Rep 9:9617. https://doi.org/10.1038/s41598-019-45989-0
doi: 10.1038/s41598-019-45989-0
pubmed: 31270349
pmcid: 6610624
Alves P, Bandaria J, Leavy MB et al (2021) Validation of a machine learning approach to estimate systemic lupus erythematosus disease activity index score categories and application in a real-world dataset. RMD Open 7:e001586. https://doi.org/10.1136/rmdopen-2021-001586
doi: 10.1136/rmdopen-2021-001586
pubmed: 34016712
pmcid: 8141448
Chen Y, Huang S, Chen T et al (2021) Machine learning for prediction and risk stratification of lupus nephritis renal flare. Am J Nephrol 52:152–160. https://doi.org/10.1159/000513566
doi: 10.1159/000513566
pubmed: 33744876
Ceccarelli F, Sciandrone M, Perricone C et al (2017) Prediction of chronic damage in systemic lupus erythematosus by using machine-learning models. PLoS One 12:e0174200. https://doi.org/10.1371/journal.pone.0174200
doi: 10.1371/journal.pone.0174200
pubmed: 28329014
pmcid: 5362169
Adamichou C, Genitsaridi I, Nikolopoulos D et al (2021) Lupus or not? SLE risk probability index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 80:758–766. https://doi.org/10.1136/annrheumdis-2020-219069
doi: 10.1136/annrheumdis-2020-219069
pubmed: 33568388
Peng J, Jury EC, Dönnes P, Ciurtin C (2021) Machine learning techniques for personalised medicine approaches in immune-mediated chronic inflammatory diseases: applications and challenges. Front Pharmacol 12:720694. https://doi.org/10.3389/fphar.2021.720694
doi: 10.3389/fphar.2021.720694
pubmed: 34658859
pmcid: 8514674
Toro-Domínguez D, Lopez-Domínguez R, García Moreno A et al (2019) Differential treatments based on drug-induced gene expression signatures and longitudinal systemic lupus erythematosus stratification. Sci Rep 9:15502. https://doi.org/10.1038/s41598-019-51616-9
doi: 10.1038/s41598-019-51616-9
pubmed: 31664045
pmcid: 6820741
Grammer AC, Ryals MM, Heuer SE et al (2016) Drug repositioning in SLE: crowd-sourcing, literature-mining and big data analysis. Lupus 25:1150–1170. https://doi.org/10.1177/0961203316657437
doi: 10.1177/0961203316657437
pubmed: 27497259
Yones SA, Annett A, Stoll P et al (2021) Interpretable machine learning identifies paediatric systemic lupus erythematosus subtypes based on gene expression data. Bioinformatics 70:2025